

# Azfar Zaman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9523114/publications.pdf>

Version: 2024-02-01

41  
papers

1,483  
citations

516710

16  
h-index

330143

37  
g-index

43  
all docs

43  
docs citations

43  
times ranked

2330  
citing authors

#	ARTICLE	IF	CITATIONS
1	Thyroid hormones and cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2017, 14, 39-55.	13.7	448
2	Thyroid Hormones and Cardiovascular Function and Diseases. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1781-1796.	2.8	272
3	FDXR is a biomarker of radiation exposure in vivo. <i>Scientific Reports</i> , 2018, 8, 684.	3.3	89
4	The Relationship of Body Mass Index to Percutaneous Coronary Intervention Outcomes. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1283-1292.	2.9	78
5	Safety and efficacy of a sirolimus-eluting coronary stent with ultra-thin strut for treatment of atherosclerotic lesions (TALENT): a prospective multicentre randomised controlled trial. <i>Lancet</i> , The, 2019, 393, 987-997.	13.7	72
6	Changes in Arterial Access Site and Association With Mortality in the United Kingdom. <i>Circulation</i> , 2016, 133, 1655-1667.	1.6	71
7	Stroke following percutaneous coronary intervention: type-specific incidence, outcomes and determinants seen by the British Cardiovascular Intervention Society 2007-12. <i>European Heart Journal</i> , 2015, 36, 1618-1628.	2.2	69
8	Effect of Levothyroxine on Left Ventricular Ejection Fraction in Patients With Subclinical Hypothyroidism and Acute Myocardial Infarction. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 249.	7.4	33
9	Impact of age on access site-related outcomes in 469,983 percutaneous coronary intervention procedures: Insights from the British Cardiovascular Intervention Society. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 86, 965-972.	1.7	30
10	Determinants and Outcomes of Stroke Following Percutaneous Coronary Intervention by Indication. <i>Stroke</i> , 2016, 47, 1500-1507.	2.0	28
11	Temporal trends and inequalities in coronary angiography utilization in the management of non-ST-Elevation acute coronary syndromes in the U.S.. <i>Scientific Reports</i> , 2019, 9, 240.	3.3	25
12	Cancer Event Rate and Mortality with Thienopyridines: A Systematic Review and Meta-Analysis. <i>Drug Safety</i> , 2017, 40, 229-240.	3.2	24
13	Lipid-lowering therapy and low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: The ACS patient pathway project. <i>Atherosclerosis Supplements</i> , 2020, 42, e49-e58.	1.2	23
14	Vascular Access Site and Outcomes in 58,870 Patients Undergoing Percutaneous Coronary Intervention With a Previous History of Coronary Bypass Surgery. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 482-492.	2.9	22
15	Primary percutaneous coronary intervention for ST elevation myocardial infarction in nonagenarians. <i>Heart</i> , 2016, 102, 1648-1654.	2.9	21
16	Outcomes Following Percutaneous Coronary Intervention in Non-ST-Segment Elevation Myocardial Infarction Patients With Coronary Artery Bypass Grafts. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e006824.	3.9	19
17	Weekend effect in acute coronary syndrome: A meta-analysis of observational studies. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019, 8, 432-442.	1.0	19
18	Percutaneous Coronary Intervention and Outcomes in Patients With Lymphoma in the United States (Nationwide Inpatient Sample [NIS] Analysis). <i>American Journal of Cardiology</i> , 2019, 124, 1190-1197.	1.6	15

#	ARTICLE	IF	CITATIONS
19	Contemporary registries on P2Y12 inhibitors in patients with acute coronary syndromes in Europe: overview and methodological considerations: Table 1. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015, 1, 232-244.	3.0	13
20	The Predictive Value of CHA2DS2-VASc Score on In-Hospital Death and Adverse Periprocedural Events Among Patients With the Acute Coronary Syndrome and Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention: A 10-Year National Inpatient Sample (NIS) Analysis. <i>Cardiovascular Revascularization Medicine</i> , 2021, 29, 61-68.	0.8	12
21	High Platelet Reactivity in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Randomised Controlled Trial Comparing Prasugrel and Clopidogrel. <i>PLoS ONE</i> , 2015, 10, e0135037.	2.5	12
22	Temporal trends and predictors of time to coronary angiography following non-ST-elevation acute coronary syndrome in the USA. <i>Coronary Artery Disease</i> , 2019, 30, 159-170.	0.7	10
23	Prospective Multicenter Randomized All-Comers Trial to Assess the Safety and Effectiveness of the Ultra-Thin Strut Sirolimus-Eluting Coronary Stent Supraflex. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e010312.	3.9	10
24	Sirolimus-eluting stents with ultrathin struts versus everolimus-eluting stents for patients undergoing percutaneous coronary intervention: final three-year results of the TALENT trial. <i>EuroIntervention</i> , 2022, 18, 492-502.	3.2	8
25	Clinical outcomes of percutaneous coronary intervention for chronic total occlusion in prior coronary artery bypass grafting patients. <i>Catheterization and Cardiovascular Interventions</i> , 2022, 99, 74-84.	1.7	7
26	Impact of established cardiovascular disease on outcomes in the randomized global leaders trial. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 1369-1378.	1.7	6
27	Ascertainment of Silent Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention (from the GLOBAL LEADERS Trial). <i>American Journal of Cardiology</i> , 2019, 124, 1833-1840.	1.6	5
28	In-hospital gastrointestinal bleeding following percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 95, 109-117.	1.7	5
29	The ultra-thin strut sirolimus-eluting coronary stent: SUPRAFLEX. <i>Future Cardiology</i> , 2021, 17, 227-237.	1.2	5
30	Survival relative to pacemaker status after transcatheter aortic valve implantation. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, E444-E452.	1.7	5
31	Antiplatelet drug selection in PCI to vein grafts in patients with acute coronary syndrome and adverse clinical outcomes: Insights from the British Cardiovascular Intervention Society database. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 92, 659-665.	1.7	4
32	Transcatheter aortic valve implantation via surgical subclavian versus direct aortic access: A United Kingdom analysis. <i>International Journal of Cardiology</i> , 2020, 308, 67-72.	1.7	4
33	Pharmacology before, during and after percutaneous coronary intervention. <i>Heart</i> , 2021, 107, 585-592.	2.9	4
34	Development of New Antithrombotic Regimens for Patients with Acute Coronary Syndrome. <i>Clinical Drug Investigation</i> , 2019, 39, 495-502.	2.2	3
35	Clinical outcomes in unselected patients treated with the PROMUS Element platinum-chromium, everolimus-eluting stent: Final five-year results from the PE PROVE Study. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 398-403.	1.7	3
36	A Randomized, double-blind, dose ranging clinical trial of intravenous FDY-5301 in acute STEMI patients undergoing primary PCI. <i>International Journal of Cardiology</i> , 2022, 347, 1-7.	1.7	3

#	ARTICLE	IF	CITATIONS
37	Lipoprotein(a): Insights for the Practicing Clinician. Journal of Clinical Medicine, 2022, 11, 3673.	2.4	2
38	The impact of diabetes on the prognostic value of left ventricular function following percutaneous coronary intervention: Insights from the British Cardiovascular Intervention Society. Catheterization and Cardiovascular Interventions, 2018, 92, E393-E402.	1.7	1
39	Prognostic Role of Sex-Specific Flow Threshold in Patients Undergoing Transcatheter Aortic Valve Replacement. Cardiovascular Revascularization Medicine, 2022, 36, 164-165.	0.8	1
40	Outcomes of 10,312 patients treated with everolimus-eluting bioresorbable scaffolds during daily clinical practice “ results from the European Absorb Consortium. Catheterization and Cardiovascular Interventions, 2021, , .	1.7	1
41	152...Circulating non-classical monocytes are preferentially depleted from the circulation immediately after reperfusion in stemi patients and are associated with patient outcomes. , 2018, , .		0